
## James E Galvin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4579108/publications.pdf Version: 2024-02-01



IAMES E CALVIN

#	Article	IF	CITATIONS
1	Rural Versus Non-Rural Residence and Psychosocial Outcomes Among Caregivers of Patients with Dementia and Related Disorders. Journal of Alzheimer's Disease, 2022, 85, 993-999.	2.6	1
2	Poor sleep accelerates hippocampal and posterior cingulate volume loss in cognitively normal healthy older adults. Journal of Sleep Research, 2022, 31, e13538.	3.2	10
3	Machine Learning Based Multimodal Neuroimaging Genomics Dementia Score for Predicting Future Conversion to Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 87, 1345-1365.	2.6	7
4	Patterns of Healthcare Use and Mortality After Alzheimer's Disease or Related Dementia Diagnosis Among Alaska Native Patients: Results of a Cluster Analysis in a Tribal Healthcare Setting. Journal of Alzheimer's Disease Reports, 2022, 6, 401-410.	2.2	0
5	Discerning rural Appalachian stakeholder attitudes toward memory screening. Aging and Mental Health, 2021, 25, 797-806.	2.8	8
6	Detecting dementia among older, ethnically diverse residents of rural subsidized housing. Geriatric Nursing, 2021, 42, 524-532.	1.9	7
7	wiSDOM: a visual and statistical analytics for interrogating microbiome. Bioinformatics, 2021, 37, 2795-2797.	4.1	4
8	The Cognitive & Leisure Activity Scale (CLAS): A new measure to quantify cognitive activities in older adults with and without cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12134.	3.7	11
9	Associations between neighborhood greenspace and brain imaging measures in non-demented older adults: the Cardiovascular Health Study. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 1575-1585.	3.1	11
10	The Effect of Baseline Patient and Caregiver Mindfulness on Dementia Outcomes. Journal of Alzheimer's Disease, 2021, 79, 1345-1367.	2.6	9
11	HCMMCNVs: hierarchical clustering mixture model of copy number variants detection using whole exome sequencing technology. Bioinformatics, 2021, 37, 3026-3028.	4.1	1
12	Comparison of the Caregiving Experience of Grief, Burden, and Quality of Life in Dementia with Lewy Bodies, Alzheimer's Disease, and Parkinson's Disease Dementia. Journal of Alzheimer's Disease, 2021, 80, 421-432.	2.6	13
13	Cognitive measures lacking in EHR prior to dementia or Alzheimer's disease diagnosis. Alzheimer's and Dementia, 2021, 17, 1231-1243.	0.8	12
14	Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the Lewy body dementia module (LBDâ€MOD). Alzheimer's and Dementia, 2021, 17, 1675-1686.	0.8	19
15	Screening for Early-Stage Alzheimer's Disease Using Optimized Feature Sets and Machine Learning. Journal of Alzheimer's Disease, 2021, 81, 355-366.	2.6	21
16	Protocol for an observational cohort study identifying factors predicting accurately end of life in dementia with Lewy bodies and promoting quality end-of-life experiences: the PACE-DLB study. BMJ Open, 2021, 11, e047554.	1.9	2
17	Associations Between Neighborhood Park Access and Longitudinal Change in Cognition in Older Adults: The Multi-Ethnic Study of Atherosclerosis. Journal of Alzheimer's Disease, 2021, 82, 221-233.	2.6	15
18	Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting. Alzheimer's Research and Therapy, 2021, 13, 124.	6.2	1

#	Article	IF	CITATIONS
19	Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. Contemporary Clinical Trials, 2021, 107, 106488.	1.8	7
20	Pre-Loss Grief in Caregivers of Older Adults with Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2021, 82, 1847-1859.	2.6	6
21	A Modified CAIDE Risk Score as a Screening Tool for Cognitive Impairment in Older Adults. Journal of Alzheimer's Disease, 2021, 82, 1755-1768.	2.6	11
22	Using Optical Coherence Tomography to Screen for Cognitive Impairment and Dementia. Journal of Alzheimer's Disease, 2021, 84, 723-736.	2.6	9
23	The Frontal Behavioral Battery: A Measure of Frontal Lobe Symptoms in Brain Aging and Neurodegenerative Disease. Journal of Alzheimer's Disease, 2021, 83, 721-739.	2.6	0
24	Retinal vessel density correlates with cognitive function in older adults. Experimental Gerontology, 2021, 152, 111433.	2.8	7
25	Biomarker Use for Dementia With Lewy Body Diagnosis. Alzheimer Disease and Associated Disorders, 2021, 35, 55-61.	1.3	8
26	Medical and Social Determinants of Brain Health and Dementia in a Multicultural Community Cohort of Older Adults. Journal of Alzheimer's Disease, 2021, 84, 1563-1576.	2.6	9
27	Validation of the Korean Quick Dementia Rating System (K-QDRS). Journal of Alzheimer's Disease, 2021, 84, 1645-1656.	2.6	2
28	Validation of AD8-Philippines (AD8-P): A Brief Informant-Based Questionnaire for Dementia Screening in the Philippines. International Journal of Alzheimer's Disease, 2021, 2021, 1-9.	2.0	2
29	The Resilience Index: A Quantifiable Measure of Brain Health and Risk of Cognitive Impairment and Dementia. Journal of Alzheimer's Disease, 2021, 84, 1729-1746.	2.6	11
30	The Vulnerability Index: A weighted measure of dementia and cognitive impairment risk. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12249.	2.4	5
31	Overcoming the COVID-19 Pandemic for Dementia Research: Engaging Rural, Older, Racially and Ethnically Diverse Church Attendees in Remote Recruitment, Intervention and Assessment. Gerontology and Geriatric Medicine, 2021, 7, 233372142110589.	1.5	5
32	Promoting Inclusivity in Dementia Education and Screening in an Ethnically Diverse, Rural Community During a Pandemic. Innovation in Aging, 2021, 5, 34-34.	0.1	0
33	Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations. Innovation in Aging, 2021, 5, 703-703.	0.1	0
34	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	2.4	12
35	Semantic Integration of Multi-Modal Data and Derived Neuroimaging Results Using the Platform for Imaging in Precision Medicine (PRISM) in the Arkansas Imaging Enterprise System (ARIES). Frontiers in Artificial Intelligence, 2021, 4, 649970.	3.4	8
36	Employing the Mocaâ€T (telephone) as a means of cognitive screening in a rural, ethnically diverse population during Covidâ€19 restrictions. Alzheimer's and Dementia, 2021, 17, e055624.	0.8	0

#	Article	IF	CITATIONS
37	ICARE ADâ€US: Design of a prospective, singleâ€arm, multicenter, noninterventional realâ€world study of aducanumab in the United States. Alzheimer's and Dementia, 2021, 17, .	0.8	0
38	Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations. Innovation in Aging, 2021, 5, 698-698.	0.1	0
39	Associations between neighborhood park space and cognition in older adults vary by US location: The Multi-Ethnic Study of Atherosclerosis. Health and Place, 2020, 66, 102459.	3.3	13
40	Intention to be screened for Alzheimer's disease in nondemented older adults: Integrated behavioral model and self-efficacy as mediation effect. Journal of Human Behavior in the Social Environment, 2020, 30, 778-796.	1.9	3
41	Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimer's Research and Therapy, 2020, 12, 137.	6.2	32
42	Diagnostic experience reported by caregivers of patients with frontotemporal degeneration. Neurology: Clinical Practice, 2020, 10, 298-306.	1.6	16
43	What older adults do with results from a communityâ€based dementia screening program. Alzheimer's and Dementia, 2020, 16, e041856.	0.8	1
44	The Positive and Negative Appraisals of Caregiving (PANAC) scale: A new measure to examine the caregiving experience in Alzheimer's disease and related dementias. Alzheimer's and Dementia, 2020, 16, e041936.	0.8	0
45	The positive and negative appraisals of caregiving (PANAC) scale: A new measure to examine the caregiving experience in Alzheimer's disease and related dementias. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12104.	3.7	6
46	<p>The Effect of Sociodemographics, Physical Function, and Mood on Dementia Screening in a Multicultural Cohort</p> . Clinical Interventions in Aging, 2020, Volume 15, 2249-2263.	2.9	5
47	Protocol for an embedded pragmatic clinical trial to test the effectiveness of Aliviado Dementia Care in improving quality of life for persons living with dementia and their informal caregivers. Contemporary Clinical Trials, 2020, 93, 106005.	1.8	4
48	Building a National Program for Pilot Studies of Embedded Pragmatic Clinical Trials in Dementia Care. Journal of the American Geriatrics Society, 2020, 68, S14-S20.	2.6	10
49	What older adults do with the results of dementia screening programs. PLoS ONE, 2020, 15, e0235534.	2.5	25
50	Diffusion MRI biomarkers of white matter microstructure vary nonmonotonically with increasing cerebral amyloid deposition. Neurobiology of Aging, 2020, 89, 118-128.	3.1	48
51	Intention to Screen for Alzheimer's Disease by Residential Locale. International Journal of Environmental Research and Public Health, 2020, 17, 2261.	2.6	1
52	Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management. Frontiers in Neurology, 2020, 11, 592302.	2.4	23
53	Using a patient-reported outcome to improve detection of cognitive impairment and dementia: The patient version of the Quick Dementia Rating System (QDRS). PLoS ONE, 2020, 15, e0240422.	2.5	13
54	The Quick Physical Activity Rating (QPAR) scale: A brief assessment of physical activity in older adults with and without cognitive impairment. PLoS ONE, 2020, 15, e0241641.	2.5	17

#	Article	IF	CITATIONS
55	The Number Symbol Coding Task: A brief measure of executive function to detect dementia and cognitive impairment. PLoS ONE, 2020, 15, e0242233.	2.5	28
56	Relationship Between Patient and Informant Assessment of Personality and Cognitive Status. Innovation in Aging, 2020, 4, 260-260.	0.1	0
57	Intention to Receive Cognitive Screening for Alzheimer's Disease in Nondemented Older Adults. Innovation in Aging, 2020, 4, 261-261.	0.1	0
58	SCREENING FOR MILD COGNITIVE IMPAIRMENT: THERE IS THE WILL BUT IS THERE A WAY?. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-2.	2.7	4
59	Title is missing!. , 2020, 15, e0242233.		0
60	Title is missing!. , 2020, 15, e0242233.		0
61	Title is missing!. , 2020, 15, e0240422.		0
62	Title is missing!. , 2020, 15, e0240422.		0
63	Title is missing!. , 2020, 15, e0240422.		0
64	Title is missing!. , 2020, 15, e0240422.		0
65	Altered dynamics of visual contextual interactions in Parkinson's disease. Npj Parkinson's Disease, 2019, 5, 13.	5.3	7
66	Differences in the Experience of Caregiving Between Spouse and Adult Child Caregivers in Dementia With Lewy Bodies. Innovation in Aging, 2019, 3, igz027.	0.1	39
67	Self-efficacy and social support for psychological well-being of family caregivers of care recipients with dementia with Lewy bodies, Parkinson's disease dementia, or Alzheimer's disease. Social Work in Mental Health, 2019, 17, 253-278.	1.0	34
68	End-of-life experiences in dementia with Lewy bodies: Qualitative interviews with former caregivers. PLoS ONE, 2019, 14, e0217039.	2.5	21
69	Reliability and Validity of SymTrak, a Multi-Domain Tool for Monitoring Symptoms of Older Adults with Multiple Chronic Conditions. Journal of General Internal Medicine, 2019, 34, 908-914.	2.6	7
70	Development and Feasibility of SymTrak, aMulti-domain Tool for Monitoring Symptoms of Older Adults in Primary Care. Journal of General Internal Medicine, 2019, 34, 915-922.	2.6	6
71	Associations between neighborhood built environment and cognition vary by apolipoprotein E genotype: Multi-Ethnic Study of Atherosclerosis. Health and Place, 2019, 60, 102188.	3.3	21
72	Perceived burden among caregivers of patients with frontotemporal degeneration in the United States. International Psychogeriatrics, 2019, 31, 1191-1201.	1.0	13

#	Article	IF	CITATIONS
73	Using Informant and Performance Screening Methods to Detect Mild Cognitive Impairment and Dementia. Current Geriatrics Reports, 2018, 7, 19-25.	1.1	33
74	P3â€522: DIFFERENCES IN CAREGIVER GRIEF AND BURDEN AMONG DEMENTIA WITH LEWY BODIES, DEMENTIA OF THE ALZHEIMER'S TYPE, AND DEMENTIA ASSOCIATED WITH PARKINSON'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1322.	0.8	0
75	P3â€214: DEMENTIA WITH LEWY BODIES CONSORTIUM: METHODOLOGY AND INITIAL SUBJECT CHARACTERISTICS. Alzheimer's and Dementia, 2018, 14, P1152.	0.8	0
76	Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. Npj Parkinson's Disease, 2018, 4, 19.	5.3	110
77	Sarcopenic obesity and cognitive performance. Clinical Interventions in Aging, 2018, Volume 13, 1111-1119.	2.9	58
78	Advancing personalized treatment of Alzheimer's disease: a call for the N-of-1 trial design. Future Neurology, 2018, 13, 151-160.	0.5	9
79	The genetics of dementia with Lewy bodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 431-440.	1.8	1
80	Alzheimer's "Prevention―vs. "Risk Reduction― Transcending Semantics for Clinical Practice. Frontiers in Neurology, 2018, 9, 1179.	2.4	28
81	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.1	2,805
82	The social and economic burden of frontotemporal degeneration. Neurology, 2017, 89, 2049-2056.	1.1	70
83	Prevention of Alzheimer's Disease: Lessons Learned and Applied. Journal of the American Geriatrics Society, 2017, 65, 2128-2133.	2.6	67
84	Use of the Quick Dementia Rating System (QDRS) as an Initial Screening Measure in a Longitudinal Cohort at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2017, 1, 9-13.	2.2	23
85	Dementia and Other Neurocognitive Disorders. , 2017, , 226-252.		0
86	The Relationship Between Mobility Dysfunction Staging and Global Cognitive Performance. Alzheimer Disease and Associated Disorders, 2016, 30, 230-236.	1.3	26
87	Onset of Mild Cognitive Impairment in Parkinson Disease. Alzheimer Disease and Associated Disorders, 2016, 30, 127-133.	1.3	23
88	Trajectory of Mobility Decline by Type of Dementia. Alzheimer Disease and Associated Disorders, 2016, 30, 60-66.	1.3	60
89	P2â€266: Early Versus Late Changes in White Matter Microstructure with Increasing Amyloid Deposition. Alzheimer's and Dementia, 2016, 12, P729.	0.8	0
90	Development and testing of the Dementia Symptom Management at Home (DSM-H) program: An interprofessional home health care intervention to improve the quality of life for persons with dementia and their caregivers. Geriatric Nursing, 2016, 37, 200-206.	1.9	27

#	Article	IF	CITATIONS
91	Validation of the Korean Version of the Lewy Body Composite Risk Score (K-LBCRS). Journal of Alzheimer's Disease, 2016, 55, 1395-1401.	2.6	3
92	Anosognosia increases caregiver burden in mild cognitive impairment. International Journal of Geriatric Psychiatry, 2016, 31, 799-808.	2.7	33
93	P2-287: The role of isolation in dementia caregiver grief. , 2015, 11, P601-P601.		0
94	P4-136: Interrelationships between cognitive and physical impairment. , 2015, 11, P830-P830.		0
95	O3-08-03: Perception differences in health status, medical care access, and Alzheimer disease between caucasians and african americans. , 2015, 11, P235-P236.		0
96	Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 316-324.	2.4	54
97	Sarcopenia and impairment in cognitive and physical performance. Clinical Interventions in Aging, 2015, 10, 663.	2.9	87
98	Comment: Too much of a good thing may still be good for your brain. Neurology, 2015, 84, 1859-1859.	1.1	0
99	The Quick Dementia Rating System (QDRS): A rapid dementia stagingÂtool. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 249-259.	2.4	100
100	Testing family-centered, function-focused care in hospitalized persons with dementia. Neurodegenerative Disease Management, 2015, 5, 203-215.	2.2	59
101	Longitudinal Associations between Physical and Cognitive Performance among Community-Dwelling Older Adults. PLoS ONE, 2015, 10, e0122878.	2.5	41
102	P4-185: UP-TITRATION TO HIGH-DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY. , 2014, 10, P856-P857.		0
103	P3-162: THE QUICK DEMENTIA RATING SYSTEM (QDRS) TO RATE PRESENCE AND SEVERITY OF NEUROCOGNITIVE DISORDERS. , 2014, 10, P688-P688.		1
104	Collaborative transdisciplinary team approach for dementia care. Neurodegenerative Disease Management, 2014, 4, 455-469.	2.2	87
105	Testing a Family entered Intervention to Promote Functional and Cognitive Recovery in Hospitalized Older Adults. Journal of the American Geriatrics Society, 2014, 62, 2398-2407.	2.6	65
106	Lewy body dementia: the impact on patients and caregivers. Alzheimer's Research and Therapy, 2014, 6, 21.	6.2	66
107	Vocalization in Dementia: A Case Report and Review of the Literature. Case Reports in Neurology, 2014, 6, 126-133.	0.7	13
108	Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in s Alzheimer's disease. SAGE Open Medicine, 2014, 2, 205031211456156.	evere 1.8	1

James E Galvin

#	Article	IF	CITATIONS
109	P3-161: STAGING OF PHYSICAL FUNCTIONAL IMPAIRMENT AS A CORRELATE OF GLOBAL COGNITION. , 2014, 10, P688-P688.		0
110	P1-177: TELEPHONE ADMINISTRATION OF THE CDR: EXCELLENT AGREEMENT WITH FACE-TO-FACE ADMINISTRATION. , 2014, 10, P364-P364.		2
111	Update on Dementia with Lewy Bodies. Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 196-204.	0.7	17
112	Mild Physical Impairment Predicts Future Diagnosis of Dementia of the Alzheimer's Type. Journal of the American Geriatrics Society, 2013, 61, 1055-1059.	2.6	53
113	Current guidelines for dementia screening: shortcomings and recommended changes. Neurodegenerative Disease Management, 2013, 3, 565-573.	2.2	13
114	Improving Physician Awareness of Alzheimer Disease and Enhancing Recruitment. Alzheimer Disease and Associated Disorders, 2012, 26, 61-67.	1.3	29
115	Optimizing diagnosis and management in mild-to-moderate Alzheimer's disease. Neurodegenerative Disease Management, 2012, 2, 291-304.	2.2	9
116	Practical clinical tool to monitor dementia symptoms: the HABC-Monitor. Clinical Interventions in Aging, 2012, 7, 143.	2.9	60
117	Longitudinal Changes in Cognition in Parkinson's Disease with and without Dementia. Dementia and Geriatric Cognitive Disorders, 2011, 31, 98-108.	1.5	35
118	Internet-Based Dementia Resources. Journal of Applied Gerontology, 2011, 30, 513-523.	2.0	7
119	Dementia screening, biomarkers and protein misfolding. Prion, 2011, 5, 16-21.	1.8	23
120	Lewy Body Dementia. Alzheimer Disease and Associated Disorders, 2010, 24, 177-181.	1.3	92
121	Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain, 2010, 133, 3290-3300.	7.6	93
122	Longitudinal Study of the Transition From Healthy Aging to Alzheimer Disease. Archives of Neurology, 2009, 66, 1254-9.	4.5	253
123	The "Portable―CDR. Alzheimer Disease and Associated Disorders, 2009, 23, 44-49.	1.3	13
124	Predictors of Physician Referral for Patient Recruitment to Alzheimer Disease Clinical Trials. Alzheimer Disease and Associated Disorders, 2009, 23, 352-356.	1.3	31
125	Psychosocial determinants of intention to screen for Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 353-360.	0.8	39
126	Effects of Galantamine on Measures of Attention. Alzheimer Disease and Associated Disorders, 2008, 22, 30-38.	1.3	30

#	Article	IF	CITATIONS
127	Evaluation of Cognitive Impairment in Older Adults. Archives of Neurology, 2007, 64, 718.	4.5	58
128	Patient's Rating of Cognitive Ability. Archives of Neurology, 2007, 64, 725.	4.5	182
129	Personality traits distinguishing dementia with Lewy bodies from Alzheimer disease. Neurology, 2007, 68, 1895-1901.	1.1	38
130	Development of a Population-based Questionnaire to Explore Psychosocial Determinants of Screening for Memory Loss and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 182-191.	1.3	16
131	Cognitive Change in Parkinson Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 302-310.	1.3	51
132	Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathologica, 2006, 112, 115-126.	7.7	85
133	The muscle protein dysferlin accumulates in the Alzheimer brain. Acta Neuropathologica, 2006, 112, 665-671.	7.7	30
134	Validity and reliability of the AD8 informant interview in dementia. Neurology, 2006, 67, 1942-1948.	1.1	357
135	Clinical phenotype of Parkinson disease dementia. Neurology, 2006, 67, 1605-1611.	1.1	222
136	Predictors of Preclinical Alzheimer Disease and Dementia. Archives of Neurology, 2005, 62, 758.	4.5	190
137	Expression profiling in the aging brain: A perspective. Ageing Research Reviews, 2005, 4, 529-547.	10.9	27
138	Neurodegenerative Diseases: Pathology and the Advantage of Single-Cell Profiling. Neurochemical Research, 2004, 29, 1041-1051.	3.3	17
139	Expression profiling and pharmacotherapeutic development in the central nervous system. Alzheimer Disease and Associated Disorders, 2004, 18, 264-9.	1.3	17
140	Dementia With Lewy Bodies. Archives of Neurology, 2003, 60, 1332-5.	4.5	16
141	Dementia and Other Neurocognitive Disorders. Advances in Psychology, Mental Health, and Behavioral Studies, 0, , 104-130.	0.1	0